argenx NV ADR (ARGX)vsAscendis Pharma AS (ASND)
ARGX
argenx NV ADR
$891.32
+5.82%
HEALTHCARE · Cap: $55.09B
ASND
Ascendis Pharma AS
$210.45
-3.83%
HEALTHCARE · Cap: $13.32B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 448% more annual revenue ($4.74B vs $865.78M). ASND leads profitability with a 57.3% profit margin vs 31.4%. ASND trades at a lower P/E of 24.7x. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
ASND
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.4%
Fair Value
$2217.64
Current Price
$891.32
$1326.32 discount
Intrinsic value data unavailable for ASND.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 104 in profit
Keeps 57 of every $100 in revenue as profit
Revenue surging 144.3% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 188.4x book value
0.0% earnings growth
Elevated debt levels
Weak financial health signals
Trading at 23.3x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : ASND
The strongest argument for ASND centers on Return on Equity, Profit Margin, Revenue Growth. Profitability is solid with margins at 57.3% and operating margin at 10.1%. Revenue growth of 144.3% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : ASND
The primary concerns for ASND are EPS Growth, Debt/Equity, Piotroski F-Score. Debt-to-equity of 1.84 is elevated, increasing financial risk.
Key Dynamics to Monitor
ASND carries more volatility with a beta of 0.48 — expect wider price swings.
ASND is growing revenue faster at 144.3% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 55/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Ascendis Pharma AS
HEALTHCARE · BIOTECHNOLOGY · USA
Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?